MX2023013364A - Regimenes de dosificacion de venetoclax para usarse en el tratamiento de los sindromes mielodisplasicos en combinacion con azacitidina. - Google Patents
Regimenes de dosificacion de venetoclax para usarse en el tratamiento de los sindromes mielodisplasicos en combinacion con azacitidina.Info
- Publication number
- MX2023013364A MX2023013364A MX2023013364A MX2023013364A MX2023013364A MX 2023013364 A MX2023013364 A MX 2023013364A MX 2023013364 A MX2023013364 A MX 2023013364A MX 2023013364 A MX2023013364 A MX 2023013364A MX 2023013364 A MX2023013364 A MX 2023013364A
- Authority
- MX
- Mexico
- Prior art keywords
- venetoclax
- azacitidine
- combination
- myelodysplastic syndromes
- dosing regimens
- Prior art date
Links
- 201000003793 Myelodysplastic syndrome Diseases 0.000 title abstract 3
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 title abstract 2
- 229960002756 azacitidine Drugs 0.000 title abstract 2
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 title abstract 2
- 229960001183 venetoclax Drugs 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Dermatology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163201749P | 2021-05-11 | 2021-05-11 | |
| PCT/US2022/028429 WO2022240786A1 (en) | 2021-05-11 | 2022-05-10 | Venetoclax dosing regimens for use in treating myelodysplastic syndromes in combination with azacitidine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023013364A true MX2023013364A (es) | 2023-11-27 |
Family
ID=84028499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023013364A MX2023013364A (es) | 2021-05-11 | 2022-05-10 | Regimenes de dosificacion de venetoclax para usarse en el tratamiento de los sindromes mielodisplasicos en combinacion con azacitidina. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220378811A1 (enExample) |
| EP (1) | EP4337183A4 (enExample) |
| JP (1) | JP2024517318A (enExample) |
| KR (1) | KR20240006659A (enExample) |
| CN (1) | CN117642161A (enExample) |
| AU (1) | AU2022273023A1 (enExample) |
| BR (1) | BR112023023677A2 (enExample) |
| CA (1) | CA3219760A1 (enExample) |
| IL (1) | IL308321A (enExample) |
| MX (1) | MX2023013364A (enExample) |
| WO (1) | WO2022240786A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220315555A1 (en) | 2009-05-26 | 2022-10-06 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3258941A4 (en) * | 2015-02-17 | 2018-09-26 | Cantex Pharmaceuticals, Inc. | Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction |
| JP7585231B2 (ja) * | 2019-04-29 | 2024-11-18 | イミュノジェン， インコーポレイテッド | 抗ｃｄ１２３免疫複合体を含む治療的組み合わせ |
| WO2020257671A1 (en) * | 2019-06-20 | 2020-12-24 | Celgene Corporation | Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome |
| WO2021037933A1 (en) * | 2019-08-28 | 2021-03-04 | Astrazeneca Ab | Combination of azd2811 nanoparticles, 5-azacitidine and venetoclax for use in the treatment of cancer |
| PH12022550835A1 (en) * | 2019-10-18 | 2023-07-03 | Forty Seven Inc | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
-
2022
- 2022-05-10 BR BR112023023677A patent/BR112023023677A2/pt unknown
- 2022-05-10 US US17/741,359 patent/US20220378811A1/en not_active Abandoned
- 2022-05-10 IL IL308321A patent/IL308321A/en unknown
- 2022-05-10 CA CA3219760A patent/CA3219760A1/en active Pending
- 2022-05-10 JP JP2023569885A patent/JP2024517318A/ja active Pending
- 2022-05-10 AU AU2022273023A patent/AU2022273023A1/en not_active Abandoned
- 2022-05-10 WO PCT/US2022/028429 patent/WO2022240786A1/en not_active Ceased
- 2022-05-10 CN CN202280048997.0A patent/CN117642161A/zh not_active Withdrawn
- 2022-05-10 MX MX2023013364A patent/MX2023013364A/es unknown
- 2022-05-10 EP EP22808145.1A patent/EP4337183A4/en not_active Withdrawn
- 2022-05-10 KR KR1020237042682A patent/KR20240006659A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL308321A (en) | 2024-01-01 |
| CN117642161A (zh) | 2024-03-01 |
| CA3219760A1 (en) | 2022-11-17 |
| JP2024517318A (ja) | 2024-04-19 |
| AU2022273023A1 (en) | 2023-11-23 |
| US20220378811A1 (en) | 2022-12-01 |
| BR112023023677A2 (pt) | 2024-02-20 |
| KR20240006659A (ko) | 2024-01-15 |
| EP4337183A1 (en) | 2024-03-20 |
| WO2022240786A1 (en) | 2022-11-17 |
| EP4337183A4 (en) | 2025-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025000105A (es) | Inhibidor de kras g12c para el tratamiento del cancer | |
| MX2019008208A (es) | Métodos para tratar el cáncer con anticuerpos anti-tim-3. | |
| DOP2023000285A (es) | Restos de administración terapéutica novedosos y usos de estos | |
| MX2016007851A (es) | Compuestos peptidomimeticos y conjugados anticuerpo-farmaco de estos. | |
| MX2022007652A (es) | Derivados espiráncos sustituidos de cadena lineal. | |
| CO2022010330A2 (es) | Dosificación de gamma-hidroxibutirato (ghb) | |
| CR20160271A (es) | Compuestos peptidométicos y sus conjugados de anticuerpo-fármaco | |
| CO2024003949A2 (es) | Inhibidores de parp1 de azetidina y pirrolidina y usos de estos | |
| BR112019004691A2 (pt) | inibidores bicíclicos em espiro da interação menina-mll | |
| MX2019008028A (es) | Regimenes de dosificacion de inmunoconjugado anti-receptor en folato 1 (folr1). | |
| BR112016007479A2 (pt) | regimes de dosagem de imunoconjugado de anti-folr1 | |
| BR112023021761A2 (pt) | Regime de dosagem de anti-ifnar1 para injeção subcutânea | |
| BR112018076639A2 (pt) | quimioterapias de combinação | |
| CL2020000270A1 (es) | Combinación terapéutica de un inhibidor tirosina quinasa del egfr de tercera generación y un inhibidor raf. | |
| UY32739A (es) | Combinaciones de agentes quimioterápicos y antagonistas dll4 y sus usos en terapia del cáncer | |
| AR106364A1 (es) | Derivados de insulina y sus usos médicos | |
| UY35465A (es) | Nuevos compuestos como inhibidores de reorganizado durante la transfección (ret) | |
| MX2021005878A (es) | Modulador de empalme de herboxidieno de conjugados de anticuerpo-farmaco y metodos de uso. | |
| CL2025001316A1 (es) | Métodos para el tratamiento de la obesidad | |
| MX2020010417A (es) | Inhibidor de ret para uso en tratar cancer que tiene una alteracion de ret. | |
| MX2019011620A (es) | Dosis y regimen para un inhibidor de la interaccion de hdm2-p53 en tumores hematologicos. | |
| MX2019014923A (es) | Régimen de dosificación. | |
| BR112023023638A2 (pt) | Regimes de dosagem de venetoclax para uso no tratamento de síndromes mielodisplásicas em combinação com um inibidor de cyp3a e azacitidina | |
| CO2022007501A2 (es) | Métodos y composiciones para el tratamiento del síndrome de rett | |
| MX2018015916A (es) | Compuestos de porfirina y composiciones útiles para el tratamiento de cáncer. |